Khalid A. Mohamedali

1.4k total citations
35 papers, 1.1k citations indexed

About

Khalid A. Mohamedali is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Khalid A. Mohamedali has authored 35 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 13 papers in Cancer Research and 12 papers in Oncology. Recurrent topics in Khalid A. Mohamedali's work include Angiogenesis and VEGF in Cancer (9 papers), Cancer, Hypoxia, and Metabolism (8 papers) and Melanoma and MAPK Pathways (4 papers). Khalid A. Mohamedali is often cited by papers focused on Angiogenesis and VEGF in Cancer (9 papers), Cancer, Hypoxia, and Metabolism (8 papers) and Melanoma and MAPK Pathways (4 papers). Khalid A. Mohamedali collaborates with scholars based in United States, China and Germany. Khalid A. Mohamedali's co-authors include Michael G. Rosenblum, Xiaohong Chen, Weibo Cai, Kai Chen, Sanjiv S. Gambhir, Qizhen Cao, Lawrence H. Cheung, Rodney E. Kellems, Walter N. Hittelman and Yu Cao and has published in prestigious journals such as Journal of Biological Chemistry, ACS Nano and Biomaterials.

In The Last Decade

Khalid A. Mohamedali

35 papers receiving 1.1k citations

Peers

Countries citing papers authored by Khalid A. Mohamedali

Since Specialization

Citations

This map shows the geographic impact of Khalid A. Mohamedali's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Khalid A. Mohamedali with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Khalid A. Mohamedali more than expected).

Fields of papers citing papers by Khalid A. Mohamedali

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Khalid A. Mohamedali. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Khalid A. Mohamedali. The network helps show where Khalid A. Mohamedali may publish in the future.

Co-authorship network of co-authors of Khalid A. Mohamedali

This figure shows the co-authorship network connecting the top 25 collaborators of Khalid A. Mohamedali. A scholar is included among the top collaborators of Khalid A. Mohamedali based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Khalid A. Mohamedali. Khalid A. Mohamedali is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	GrB-Fc-KS49, an anti-EMP2 granzyme B fusion protein therapeutic alters immune cell infiltration and suppresses breast cancer growth 2024 ·Journal for ImmunoTherapy of Cancer ·Khalid A. Mohamedali, (unknown), (unknown), (unknown), (unknown), (unknown), Ann M. Chan, Lawrence H. Cheung, (unknown), Sergio Duarte, Ana Álvarez‐Cienfuegos, David Casero, Michael G. Rosenblum, Madhuri Wadehra	3
2	Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B 2019 ·Journal of Experimental & Clinical Cancer Research ·Lawrence H. Cheung, Yunli Zhao, Ana Álvarez‐Cienfuegos, Khalid A. Mohamedali, Yu Cao, Walter N. Hittelman, Michael G. Rosenblum	18
3	Light-enhanced VEGF121/rGel: A tumor targeted modality with vascular and immune-mediated efficacy 2018 ·Journal of Controlled Release ·Anette Weyergang, (unknown), Ellen Skarpen, Qian Peng, Khalid A. Mohamedali, (unknown), Lawrence H. Cheung, Michael G. Rosenblum, Johannes Waltenberger, Kristian Berg	15
4	Development of Human Serine Protease-Based Therapeutics Targeting Fn14 and Identification of Fn14 as a New Target Overexpressed in TNBC 2014 ·Molecular Cancer Therapeutics ·Hong Zhou, Khalid A. Mohamedali, Ana M. González-Angulo, Yu Cao, Mary Migliorini, Lawrence H. Cheung, Janine LoBello, Xiudong Lei, Yuan Qi, Walter N. Hittelman, Jeffrey A. Winkles, Nhan L. Tran, Michael G. Rosenblum	21
5	Photochemical internalization augments tumor vascular cytotoxicity and specificity of VEGF121/rGel fusion toxin 2014 ·Journal of Controlled Release ·Anette Weyergang, Lawrence H. Cheung, Michael G. Rosenblum, Khalid A. Mohamedali, Qian Peng, Johannes Waltenberger, Kristian Berg	23
6	The Functionalized Human Serine Protease Granzyme B/VEGF121 Targets Tumor Vasculature and Ablates Tumor Growth 2013 ·Molecular Cancer Therapeutics ·Khalid A. Mohamedali, Yu Cao, Lawrence H. Cheung, Walter N. Hittelman, Michael G. Rosenblum	12
7	Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles 2012 ·Biomaterials ·Fan Zhang, Xinglu Huang, Lei Zhu, Ning Guo, Gang Niu, Magdalena Swierczewska, Seulki Lee, Hong Xu, Andrew Y. Wang, Khalid A. Mohamedali, Michael G. Rosenblum, Guangming Lu, Xiaohong Chen	90
8	Pharmacodynamics, tissue distribution, toxicity studies and antitumor efficacy of the vascular targeting fusion toxin VEGF121/rGel 2012 ·Biochemical Pharmacology ·Khalid A. Mohamedali, Gang Niu, Troy A. Luster, Philip E. Thorpe, Haokao Gao, Xiaohong Chen, Michael G. Rosenblum	3
9	The TWEAK Receptor Fn14 Is a Therapeutic Target in Melanoma: Immunotoxins Targeting Fn14 Receptor for Malignant Melanoma Treatment 2012 ·Journal of Investigative Dermatology ·Hong Zhou, Sühendan Ekmekçioglu, John W. Marks, Khalid A. Mohamedali, Kaushal Asrani, (unknown), Sharron A.N. Brown, Emily H. Cheng, Michele B. Weiss, Walter N. Hittelman, Nhan L. Tran, Hideo Yagita∥, Jeffrey A. Winkles, Michael G. Rosenblum	47
10	Inhibition of Prostate Cancer Osteoblastic Progression with VEGF121/rGel, a Single Agent Targeting Osteoblasts, Osteoclasts, and Tumor Neovasculature 2011 ·Clinical Cancer Research ·Khalid A. Mohamedali, Zhigang Li, Michael W. Starbuck, Xinhai Wan, Jun Yang, (unknown), Wendy Zhang, Michael G. Rosenblum, Nora M. Navone	18
11	Cell-Targeting Fusion Constructs Containing Recombinant Gelonin 2011 ·Methods in enzymology on CD-ROM/Methods in enzymology ·Mi-Ae Lyu, Yu Cao, Khalid A. Mohamedali, Michael G. Rosenblum	23
12	Sensitive Angiogenesis Imaging of Orthotopic Bladder Tumors in Mice Using a Selective Magnetic Resonance Imaging Contrast Agent Containing VEGF121/rGel 2011 ·Investigative Radiology ·Eun-Jin Cho, Jaemoon Yang, Khalid A. Mohamedali, Eun‐Kyung Lim, Eunjung Kim, Carol Farhangfar, Jin‐Suck Suh, Seungjoo Haam, Michael G. Rosenblum, Yong‐Min Huh	30
13	Cytotoxicity of VEGF121/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2 2011 ·BMC Cancer ·Khalid A. Mohamedali, Sophia Ran, Candelaria Gomez‐Manzano, Latha Ramdas, Jing Xu, (unknown), Lawrence H. Cheung, Walter N. Hittelman, Wei Zhang, Johannes Waltenberger, Philip E. Thorpe, Michael G. Rosenblum	14
14	Imaging of VEGF Receptor in a Rat Myocardial Infarction Model Using PET 2008 ·Journal of Nuclear Medicine ·Martin Rodriguez‐Porcel, Weibo Cai, Olivier Gheysens, Jürgen K. Willmann, Kai Chen, Hui Wang, Ian Y. Chen, Lina He, Joseph C. Wu, Zibo Li, Khalid A. Mohamedali, (unknown), Michael G. Rosenblum, Xiaohong Chen, Sanjiv S. Gambhir	85
15	Inhibition of Prostate Tumor Growth and Bone Remodeling by the Vascular Targeting Agent VEGF121/rGel 2006 ·Cancer Research ·Khalid A. Mohamedali, Ann T. Poblenz, Charles R. Sikes, Nora M. Navone, Philip E. Thorpe, Bryant G. Darnay, Michael G. Rosenblum	25
16	Overexpression of biologically active VEGF121 fusion proteins in Escherichia coli 2006 ·Journal of Biotechnology ·(unknown), Khalid A. Mohamedali, Lawrence H. Cheung, Michael G. Rosenblum	13
17	The Vascular-Targeting Fusion Toxin VEGF121/rGel Inhibits the Growth of Orthotopic Human Bladder Carcinoma Tumors 2005 ·Neoplasia ·Khalid A. Mohamedali, Daniel Kedar, Paul Sweeney, Ashish M. Kamat, Darren W. Davis, Beryl Y. Eve, Samuel Huang, Philip E. Thorpe, Colin P. Dinney, Michael G. Rosenblum	30
18	Vascular Targeting of Ocular Neovascularization with a Vascular Endothelial Growth Factor121/Gelonin Chimeric Protein 2005 ·Molecular Pharmacology ·Hideo Akiyama, Khalid A. Mohamedali, Raquel Lima e Silva, Shu Kachi, JiKui Shen, (unknown), Naoyasu Umeda, Sean F. Hackett, Sadia Aslam, (unknown), Hong Lai, Michael G. Rosenblum, Peter A. Campochiaro	22
19	The Vascular-Ablative Agent VEGF121/rGel Inhibits Pulmonary Metastases of MDA-MB-231 Breast Tumors 2005 ·Neoplasia ·Sophia Ran, Khalid A. Mohamedali, Troy A. Luster, Philip E. Thorpe, Michael G. Rosenblum	28
20	Probing the Functional Role of Two Conserved Active Site Aspartates in Mouse Adenosine Deaminase 1996 ·Biochemistry ·(unknown), Khalid A. Mohamedali, David K. Wilson, Zengyi Chang, Rodney E. Kellems, Florante A. Quiocho, Frederick B. Rudolph	43

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact